Diffuse Large B Cell Lymphoma: Symptoms, Stages, Treatment, and Prognosis

What Is Diffuse Large B Cell Lymphoma?

Diffuse large b-cell lymphoma (dlbcl) is a cancer of B lymphocytes, a type of white blood cell involved in the immune system. Under a microscope, the cancer cells are larger than normal lymphocytes and have a characteristic diffuse growth pattern. DLBCL is considered an aggressive or fast-growing form of non-Hodgkin lymphoma.

The World Health Organization’s current classification of haematolymphoid tumors includes diffuse large B-cell lymphoma, not otherwise specified, among large B-cell lymphomas, along with several biologically distinct large B-cell lymphoma entities. This classification reflects the importance of pathology and molecular findings in identifying the specific lymphoma subtype.

DLBCL most often occurs in adults, particularly older adults, although it can occur at different ages. It may involve lymph nodes, the spleen, bone marrow, liver, gastrointestinal tract, skin, or other tissues.

Where Does DLBCL Fit Within Blood Cancers?

Blood Cancer is a broad term covering cancers that arise in blood-forming tissues, blood cells, or the lymphatic system. Leukemia, lymphoma, and multiple myeloma are commonly grouped within this broad category, although they are different diseases.

For someone searching for Types of Blood Cancer, it is important to understand that lymphoma itself contains many subtypes.

Lymphoma refers to cancers that begin in cells of the lymph system. The two broad categories are Hodgkin lymphoma and non-Hodgkin lymphoma. Non-Hodgkin lymphoma includes numerous B-cell and T-cell subtypes.

DLBCL and Other Types of Lymphoma

Non-Hodgkin Lymphoma is not a single disease. It includes many different lymphomas that can behave differently depending on the cells involved and their biological characteristics.

Hodgkin Lymphoma, for example, is a distinct category from non-Hodgkin lymphoma and includes classical Hodgkin lymphoma and other recognized forms. Comparing Hodgkin VS Non-Hodgkin Lymphoma requires looking at differences in cell type, pathology, disease behavior, and treatment.

Within non-Hodgkin lymphoma, several B-cell and T-cell diseases may be encountered:

• B-Cell Lymphoma includes several diseases arising from B lymphocytes, including DLBCL and follicular lymphoma.
• T-Cell Lymphoma refers to lymphomas arising from T lymphocytes and represents a different group of diseases.
• Burkitt Lymphoma is another aggressive B-cell lymphoma with distinct biological characteristics.
• Follicular Lymphoma is generally considered an indolent B-cell lymphoma, although transformation to a more aggressive lymphoma can occur.
• Small Lymphocytic Lymphoma is closely related to chronic lymphocytic leukemia.
• MALT Lymphoma is a form of extranodal marginal zone lymphoma involving mucosa-associated lymphoid tissue.
• Marginal Zone Lymphoma includes several generally slower-growing B-cell lymphomas.
• Anaplastic Large Cell Lymphoma is a type of T-cell lymphoma.
• Cutaneous T-Cell Lymphoma describes a group of T-cell lymphomas in which the skin is a major site of involvement.

The World Health Organization’s classification demonstrates how broad the lymphoma category is and why identifying the precise subtype is an important part of diagnosis.

What Are the Symptoms of DLBCL?

The symptoms of DLBCL can vary depending on where the lymphoma develops and how quickly it grows.

Common diffuse large b-cell lymphoma symptoms can include:

• Rapidly enlarging lymph nodes
• Fever without an obvious infection
• Drenching night sweats
• Unexplained weight loss
• Fatigue
• A mass or swelling in an affected area
• Pain or pressure caused by involvement of a particular organ or tissue

NCI lists swollen lymph nodes, fever, drenching night sweats, fatigue, and unexplained weight loss among symptoms that can occur with non-Hodgkin lymphoma. Symptoms can also depend on the location and size of the lymphoma.

For example, persistent swollen cervical lymph nodes may be noticed in the neck. However, enlarged lymph nodes can have many causes, including infections and other non-cancerous conditions. A swollen lymph node alone does not establish a diagnosis of lymphoma.

Some people may experience symptoms related to extranodal disease. For instance, lymphoma involving the gastrointestinal tract, skin, bone, or another organ can produce symptoms associated with that location.

How Is Diffuse Large B Cell Lymphoma Diagnosed?

Although how is diffuse large b cell lymphoma diagnosed is an important search question, the diagnosis generally requires more than symptoms or imaging alone.

A tissue biopsy is central to diagnosing lymphoma because a pathologist needs to examine the abnormal cells and determine the specific lymphoma type. Additional laboratory, imaging, and molecular tests may then help characterize the disease and determine its extent.

The diagnostic workup may include:

Biopsy

A biopsy provides tissue for microscopic examination. Pathologists evaluate the cells and use additional testing, such as immunohistochemistry or other laboratory methods, when needed to classify the lymphoma.

Blood Tests

Blood tests may provide information about overall health and help identify findings relevant to prognosis or treatment planning. LDH, for example, is one of the clinical factors considered in prognostic assessment for aggressive lymphomas.

Imaging

CT and PET imaging can help determine where lymphoma is located and how extensively it has spread. PET/CT is commonly incorporated into lymphoma staging and response assessment.

Additional Testing

Depending on the individual situation, physicians may order additional laboratory, molecular, or other tests. These can help distinguish DLBCL from other lymphoma subtypes and identify biological features that may affect treatment decisions.

Because several lymphoma subtypes can appear similar clinically, an accurate pathological diagnosis is essential before treatment is selected.

What Is Diffuse Large B Cell Lymphoma Staging?

Diffuse large b cell lymphoma staging describes the extent of lymphoma in the body at diagnosis. Staging helps physicians understand whether disease is limited to one area or involves multiple lymph-node regions or extranodal organs.

The Lugano classification is used for staging Hodgkin and non-Hodgkin lymphomas. Broadly, lymphoma can be classified from stage I through stage IV.

Stage I

Stage I generally indicates involvement of a single lymphatic site, such as one lymph-node region, or a single extranodal site in certain circumstances.

Stage II

Stage II generally involves two or more lymph-node regions on the same side of the diaphragm. Some presentations involving an extranodal site or bulky disease have additional staging considerations.

Stage III

Stage III generally indicates lymph-node involvement on both sides of the diaphragm. Other organs or tissues may also be involved depending on the individual presentation.

Stage IV

Stage IV indicates more extensive disease involving one or more extranodal organs or tissues, such as bone marrow, liver, or other sites, according to lymphoma staging criteria.

Staging is important, but it is not the only factor doctors consider. Age, performance status, LDH level, tumor size, number of extranodal sites, disease biology, and other findings can also contribute to prognosis and treatment planning.

What Does Stage 4 Diffuse Large B Cell Lymphoma Mean?

A diagnosis of stage 4 diffuse large b cell lymphoma means the lymphoma meets criteria for stage IV disease, generally because it involves one or more extranodal organs or tissues in a pattern consistent with advanced-stage lymphoma.

Stage IV describes the extent of disease; it does not by itself describe how an individual will respond to treatment.

This is an important distinction because patients sometimes interpret stage IV to mean that treatment is no longer possible. For DLBCL, systemic treatment is used because the disease can occur in multiple parts of the body, and treatment decisions are based on the complete clinical picture rather than stage alone.

What Is Bulky Lymphoma?

Bulky Lymphoma refers to lymphoma involving a large mass of disease. The definition of bulky disease can vary according to lymphoma type and staging criteria. For DLBCL, measurements around 10 cm have commonly been used as a definition of bulky disease in staging discussions.

Bulky disease is considered alongside other clinical findings rather than being interpreted as a diagnosis or stage by itself.

Is Diffuse Large B Cell Lymphoma Hereditary?

The answer requires a distinction between inherited cancer susceptibility and the biological changes that occur within lymphoma cells. Having a family history of lymphoma does not necessarily mean that DLBCL itself is inherited. Genetic counselling may be appropriate in specific circumstances, particularly when there is a notable family history or other features suggesting inherited cancer susceptibility.

Is Diffuse Large B Cell Lymphoma Curable?

DLBCL is an aggressive lymphoma, but it can respond to treatment, and some patients achieve long-term remission. Stage, disease biology, overall health, treatment response, and whether the lymphoma returns all affect the clinical picture.

What Is the Treatment for DLBCL?

Diffuse large b cell lymphoma treatment depends on several factors, including the specific lymphoma subtype, stage, biological characteristics, age, overall health, and whether the disease is newly diagnosed, refractory, or recurrent.

For newly diagnosed aggressive B-cell lymphoma, treatment may involve combination chemotherapy and antibody-based therapy. R-CHOP has been an established treatment regimen for many patients with DLBCL, while other regimens may be considered depending on disease characteristics and clinical circumstances.

R-CHOP combines:

• Rituximab
• Cyclophosphamide
• Doxorubicin
• Vincristine
• Prednisone

Other approaches may be considered for selected patients. NCI’s treatment information includes polatuzumab vedotin combined with R-CHP among approaches evaluated for aggressive B-cell lymphoma.

Treatment can be different when lymphoma does not respond adequately to initial therapy or returns after remission. Depending on the situation, treatment may include additional systemic therapies, targeted or immune-based treatments, cellular therapies such as CAR T-cell therapy, stem cell transplantation, radiation in selected circumstances, or clinical trial participation.

Treatment decisions should be individualized by a hematologist or oncologist who can interpret pathology, imaging, laboratory results, and the patient’s overall health together.

Understanding DLBCL Prognosis

Diffuse large b cell lymphoma prognosis varies from one person to another. Doctors consider multiple factors rather than using stage alone to estimate outlook.

Important prognostic factors can include:

• Age
• Disease stage
• Performance status
• LDH level
• Number of extranodal sites
• Tumor characteristics
• Disease biology
• Response to treatment

The International Prognostic Index, or IPI, incorporates several clinical factors, including age, stage, performance status, LDH, and the number of extranodal sites. It is used as a prognostic tool for aggressive lymphomas.

A prognostic score should not be interpreted as an individual prediction. It is a population-based clinical tool that helps physicians evaluate risk alongside other information.

What Are DLBCL Survival Rates?

Published diffuse large b cell lymphoma survival rates describe outcomes among groups of patients rather than predicting exactly what will happen to one person.

According to the American Cancer Society, among people in the United States diagnosed with DLBCL from 2015 through 2021, the 5-year relative survival rate was:

These figures are population-level statistics. The American Cancer Society cautions that survival estimates do not account for every factor that can influence an individual’s outlook, including age, overall health, lymphoma characteristics, and response to treatment. The figures also reflect people diagnosed in earlier years, so they may not fully represent outcomes with the newest treatments.

For that reason, survival statistics are best understood as general reference information rather than an individualized forecast.

Clinical Trials and Ongoing Research for DLBCL

Research into DLBCL continues to examine new treatment combinations, targeted therapies, immune-based approaches, cellular therapies, and strategies for patients whose disease has returned or has not responded to initial treatment.

Clinical trials are research studies designed to answer specific medical questions. Some evaluate new therapies, while others study new combinations, treatment timing, biomarkers, or approaches to managing disease.

Patients may discuss ongoing research studies with their healthcare team to determine whether a particular study matches their diagnosis, previous treatment, disease status, and eligibility requirements.

For people specifically researching research opportunities, Diffuse Large B Cell Lymphoma Clinical trials can be a useful starting point for locating studies focused on this disease.

Research organizations and clinical research sites may also participate in studies involving lymphoma. NHO Revive is conducting clinical trials that may offer research opportunities for eligible patients. Those interested in learning more can explore the available trials to see whether any may be relevant to their diagnosis and treatment history.

Conclusion

Diffuse Large B Cell Lymphoma is a fast-growing form of B-cell non-Hodgkin lymphoma that can affect lymph nodes as well as other tissues and organs. While the disease can progress quickly, treatment approaches are available, and the outlook varies considerably depending on disease biology, stage, patient characteristics, and response to therapy.

Understanding DLBCL cancer, its symptoms, diagnostic process, staging, treatment options, and prognostic factors can help patients have more informed conversations with their healthcare teams. Importantly, a stage or survival statistic should not be interpreted in isolation.